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Abstract
Background: Drug-resistant tuberculosis (DR-TB) is undermining TB control in South Africa. However, there are hardly any
data about the cost of treating DR-TB in high burden settings despite such information being quintessential for the rational
planning and allocation of resources by policy-makers, and to inform future cost-effectiveness analyses.
Methodology: We analysed the comparative 2011 United States dollar ($) cost of diagnosis and treatment of drug sensitive
TB (DS-TB), MDR-TB and XDR-TB, based on National South African TB guidelines, from the perspective of the National TB
Program using published clinical outcome data.
Principal Findings: Assuming adherence to national DR-TB management guidelines, the per patient cost of XDR-TB was
$26,392, four times greater than MDR-TB ($6772), and 103 times greater than drug-sensitive TB ($257). Despite DR-TB
comprising only 2.2% of the case burden, it consumed ,32% of the total estimated 2011 national TB budget of US $218
million. 45% and 25% of the DR-TB costs were attributed to anti-TB drugs and hospitalization, respectively. XDR-TB
consumed 28% of the total DR-TB diagnosis and treatment costs. Laboratory testing and anti-TB drugs comprised the
majority (71%) of MDR-TB costs while hospitalization and anti-TB drug costs comprised the majority (92%) of XDR-TB costs.
A decentralized XDR-TB treatment programme could potentially reduce costs by $6930 (26%) per case and reduce the total
amount spent on DR-TB by ,7%.
Conclusion/Significance: Although DR-TB forms a very small proportion of the total case burden it consumes a
disproportionate and substantial amount of South Africa’s total annual TB budget. These data inform rational resource
allocation and selection of management strategies for DR-TB in high burden settings.
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Tuberculosis (TB) remains a major public health crisis in sub-
Saharan Africa despite declining global TB incidence rates [1].
Achieving the United Nations Millennium Development goal to
reduce the burden of TB by 50% in 2015 seems unlikely in this
region [2]. This is due to several reasons including unsuccessful
treatment programmes, the HIV epidemic, increasing economic
deprivation and the emergence of drug resistant TB (DR-TB)
[3,4]. Multidrug-resistant TB (MDR-TB), defined as culture-
confirmed resistance to rifampicin and isoniazid, comprises ,3%
of new and retreatment TB cases in Africa [1]. Approximately 5 to
10% of all MDR-TB cases are extensively-drug-resistant TB
(XDR-TB), defined as MDR-TB plus additional culture-con-
firmed resistance to a fluoroquinolone and an injectable agent (2nd
line aminoglycoside or capreomycin) [3]. The situation, fuelled by
high transmission rates and HIV co-infection, is particularly dire
in South Africa which has the one of the highest TB incidence
rates and the 5th highest DR-TB burden globally [1,5].
Compared to drug-susceptible TB (DS-TB), MDR-TB and
XDR-TB requires longer, more toxic treatment, and is associated
with poorer outcomes (less than 20% of XDR-TB cases culture-
convert in South Africa [6–8] compared to other high burden
settings where culture conversion rates were higher [9]). Drug
costs for treatment of DR-TB are considerably higher and divert
resources away from managing a national TB program (NTP). In
2011, the NTP budget in South Africa was approximately US$218
million and a crude preliminary estimate suggests that almost half
was allocated to managing MDR-TB [1,10]. More accurate per
case and total estimates are required by NTPs and policy makers
for rational planning and allocation of resources, to determine
optimal preventative and management strategies, to prioritise
competing health care issues, and to inform future cost-effective-
ness analyses. These data are also relevant to the proposed scaling
up of TB diagnostic capacity using nucleic acid amplification
platforms such as Xpert MTB-RIF (Cepheid, USA), and
Genotype MTBDRplus and MTBDRsl assays (Hain Lifesciences,
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Germany) as such tests are likely to sharply increase the number of
newly diagnosed cases of DR-TB [11]. However, there are limited
data globally about the cost of treating multi-drug resistant TB
[12–17] and none about management-related costs in South
Africa. Furthermore, there are no studies that have directly
assessed the cost of XDR-TB in South Africa or elsewhere.
To address these gaps in our knowledge we performed a
comprehensive cost analysis of MDR-TB and XDR-TB in the
Western Cape province of South Africa, based on the current
national DR-TB guidelines. As TB treatment costs in different
provinces are similar, our analysis reflects costs of DR-TB
treatment in South Africa in general. Additionally, we evaluated
the costs of a hypothetical decentralized treatment programme for
XDR-TB that could potentially reduce the financial burden on
South Africa’s healthcare system.
Methods
We performed a cost analysis to determine the economic impact
of DR-TB on the National TB Programme in South Africa. The
analysis was performed from the perspective of the South African
National TB Program which incurs all TB related management
costs, including ADR management, surgery, drugs, hospitalization
and diagnostic/monitoring tests. Strict adherence to National
South African DR-TB management guidelines was assumed in the
analysis. All direct and indirect medical and non-medical costs
were included for the year 2011. The time horizon for the analysis
was 6 months for DS-TB and 24 months for DR-TB, which is the
length of a full course of anti-DS-TB and anti-DR-TB treatment,
respectively. Future costs were adjusted for inflation using the
South African Consumer Price Index where appropriate [18]. All
costs were expressed in 2011 $US at an exchange rate of
$1USD = ZAR7.05 [19]. Estimates of DS-TB, MDR-TB and
XDR-TB disease outcomes were taken from published cohort
studies specifically conducted in South Africa [1,6–8,20–30].
Component costs are shown in table 1.
Unit Costs
Inpatient, outpatient and clinic costs. The Western Cape
Province has the third highest incidence of DR-TB in South Africa
and accounts for 15% of DR-TB cases [5]. Brooklyn Chest
Hospital (BCH) is a designated DR-TB hospital which provides
inpatient and outpatient services for the majority of MDR-TB and
XDR-TB patients in the Western Cape. Hospital-associated costs
were provided by BCH and are assumed to be representative of
this type of facility in South Africa. Inpatient and outpatient costs
were calculated using a WHO standardised tool for economic
analyses [31]. Personnel costs, including nursing, medical, patient
support and other general staff, were obtained from provincial
government salary scales and included basic salaries, medical aid
contributions and housing allowances. Capital costs included all
buildings, equipment, vehicles and furniture. Building and vehicle
costs were calculated based on the current replacement costs at
BCH, according to standard protocols [31]. Capital costs were
annualized at a discount rate of 3%. The useful lifetime was
assumed to be 50 years for buildings and 10 years for vehicles and
equipment. Outpatient services were assumed to use a proportion
of hospital overhead costs determined by standard methods [31].
Medical consumables and other recurrent overhead costs,
including utilities and maintenance costs were obtained from
2011 BCH expenditure reports. Ancillary costs, including kitchen
and laundry services, were attributable to inpatient costs only and
were also obtained from BCH expenditure reports. Outpatient
services were assumed to use a proportion of hospital overhead
costs [31]. Total inpatient and outpatient costs were divided by the
total number of BCH inpatient days and outpatient visits to
calculate the cost per inpatient day and outpatient visit,
respectively. In South Africa, the majority of DS-TB cases are
diagnosed and treated at primary care clinics under the National
Directly Observed Treatment Short-Course (DOTS) Programme.
Primary care clinic visit costs were calculated, in a similar manner
to inpatient and outpatient costs, using data from two TB clinics
located in the Cape Town Metro region, Langa Clinic and Chapel
Street Clinic. An inpatient day at BCH costs $56.07 whereas an
outpatient visit costs $21.16. The cost of a primary care clinic visit
(average of two clinics) was $6.64. The cost of a DOTS clinic visit
was $1.10 (DS-TB). M/XDR-TB and DS-TB retreatment patients
incur a higher DOTS clinic visit cost as they require a nurse for
administering injectable drugs ($2.01 per visit).
Drug costs. Drug costs were based on current government
tender prices and include those prescribed in standard treatment
regimens for DS-TB, MDR-TB and XDR-TB. DR-TB regimens
are based on country specific drug resistance profiles and use of
second line drugs [5]. DS-TB drugs include four first line agents
isoniazid, rifampicin, ethambutol and pyrazinamide as well as
streptomycin for retreatment cases. MDR-TB and XDR-TB
require much longer treatment duration using second and third
line anti-tuberculosis agents. MDR-TB patients use kanamycin in
the intensive treatment phase and ethionamide, pyrazinimide,
moxifloxacin and terizidone in both the intensive and continuation
phase. Primary XDR –TB patients are treated with capreomycin
in the intensive phase and ethionamide, pyrazinimide, moxiflox-
acin, clofazimine, terizidone and para-aminosalycilic acid (PAS) in
both intensive and continuation phases. Acquired XDR-TB
patients substitute ethionamide and terizidone for augmentin,
clarithromycin and high dose isoniazid in their treatment regimen.
HIV ARV drug costs have been excluded from the analysis as the
incremental costs would be zero for MDR-TB, XDR-TB and DS-
TB if HIV ARV therapy was assessed for an equivalent period.
However, the inclusion of HIV ARV costs was assessed in the
sensitivity analysis. Total treatment regimen costs were calculated
based on these standardised regimens for a 50–70 kg patient given
treatment 6 days a week.
Diagnostic and monitoring test costs. The costs of all
laboratory based tests, for bacteriological assessment, drug
susceptibility testing (DST), HIV and adverse drug reaction
(ADR) monitoring were provided by the National Health
Laboratory Service (NHLS). The NHLS is a reference lab which
provides services for the public healthcare system so these costs
represent the actual costs incurred by the NTP. HIV monitoring
test costs were included in the analysis according to current DR-
TB management guidelines [5]. Test costs obtained directly from
the NHLS have been used in previous health economic analyses
[11,32]. The cost of a chest X-ray (CXR) was obtained from
Groote Schuur Hospital (a CXR referral centre for primary care
clinics in Cape Town). The cost of an audiogram was calculated
from BCH data using an ingredient’s approach. The cost of an
Xpert MTB-RIF was calculated from WHO estimates [33] and
South African specific data using an ingredient’s approach.
Specimen transport costs were calculated separately using data
from BCH according to standard protocols [31] and incorporated
in the total test costs. Total test costs were determined by
multiplying unit costs provided by the NHLS by the frequency of
tests performed for the period of treatment as recommended in the
national TB and Drug Resistant TB policy guidelines [5,34]
(Table S1).
Adverse drug reaction (ADR) costs. An ADR, due to either
first-line or second-line anti-TB drugs, was assumed to be 3 weeks
Cost of Drug Resistant TB in South Africa
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Table 1. Costs of components associated with diagnosis and treatment of drug sensitive, multi-drug resistant and extensively
drug resistant tuberculosis.
Cost Component Cost ($US) Source
Inpatient stay (per day) BCH expenditure reports, Department of Health,
BCH statistical reports, staff interviews
Capital costs (Buildings and Equipment) $4.70
Nursing & Medical staff $18.42
Support staff (OT, PT, Dietician, Psychologist, Data Capturer, etc) $4.77
Administrative staff $2.93
Staff overhead (excluding administrative staff) $7.20
Ancillary (Kitchen & Laundry) $9.23
Recurrent medical consumables $3.91
Non personnel recurrent overheads (utilities and other general supplies) $4.93
Total $56.07
Outpatient visit (per visit) BCH expenditure reports, Department of Health,
BCH statistical reports, staff interviews
Capital costs (Buildings and Equipment) $1.59
Nursing & Medical staff $6.13
Support staff (OT, PT, Dietician, Psychologist, Data Capturer, etc.) $7.15
Administrative staff $0.97
Staff overhead (excluding administrative staff) $2.39
Recurrent medical consumables $1.30
Non personnel recurrent overheads (utilities and other general supplies) $1.64
Total $21.16
Clinic visit (per visit) Langa and Chapel St Clinic expenditure reports,
Cape Town City Health, clinic staff interviews
Capital costs (Buildings and Equipment) $0.61
Staff (Nursing, Medical and General administrative staff) $4.44
Recurrent medical consumables $0.90
non personnel recurrent overheads (utilities and other general supplies) $0.69
Total $6.64
10 minute DOTS worker visit (per visit) $1.10 Provincial government salary scales
Drugs BCH pharmacy, Cape Town City Health
DS-TB
2 mth Intensive (RHZE) $16.77
4 mth Continuation (RH) $20.96
DS-TB Retreatment
3 mth Intensive (RHZES) $135.45
5 mth Continuation (RHE) $53.03
MDR-TB
6 mth Intensive (Km-Z-Mxf-Eto-Trd) $1,438.03
18 mth Continuation (Z-Mxf-Eto-Trd) $3,671.48
XDR-TB Primary
6 mth Intensive (Cm-Z-Mxf-Eto-Trd-PAS-Cfz) $5,272.91
18 mth Continuation (Cm-Z-Mxf-Eto-Trd-PAS-Cfz) $15,015.62
XDR-TB Acquired
6 mth Intensive (Cm-Z-Mxf-Clm-Aug-hdH-PAS-Cfz) $4,884.80
18 mth Continuation (Z-Mxf-Clm-Aug-hdH-PAS-Cfz) $13,406.14
Tests National Health Laboratory Services, Groote Schuur
Hospital, WHO
Auramine Fluorescent Smear Microscopy $3.71
MGIT 960 liquid Culture $14.02
Xpert MTB-RIF $21.39
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in duration and the total cost included that of ancillary drugs, extra
weekly monitoring tests and hospital outpatient or clinic visits
during this timeframe, in accordance with national guidelines
[5,34,35]. The incidence of ADRs associated with DS-TB, MDR-
TB and XDR-TB treatment was taken from the literature
[6,25,26]. Additionally, we assumed that some patients who
develop severe ADRs [30% for MDR-TB and XDR-TB [6,29];
10% for DS-TB [25]] will require hospitalization for 2 weeks [36].
Given that first line drugs are associated with less severe ADRs
[37] and DS-TB patients are generally not as sick as DR-TB
patients, we assume that DS-TB associated ADRs only require
1 week hospitalization [38]. We did not account for the reduction
in costs associated with lowering the dosage or withdrawing TB
drugs and we assumed that substitution of drugs will occur at no
additional cost [39]. Additionally, we assumed the same ADRs
occur with the same frequency in HIV infected and HIV
uninfected individuals.
Surgery costs. The cost of a pneumonectomy procedure was
used to represent the cost of surgical resection in DR-TB cases.
This cost was provided by the Groote Schuur Surgical Depart-
ment and included the costs of facilities, medication, personnel and
tests associated with surgery.
Death-related costs. Death-related costs were only incurred
by inpatients that died in hospital and included the cost for
removal of the body from the hospital premises. We assumed all
other death related costs to be borne by the patient.
Diagnostic and Treatment Algorithms
Protocols for the diagnosis and treatment of DS-TB, MDR-TB
and XDR-TB were followed according to South African National
Department of Health Guidelines [5,34]. Treatment associated
outcomes have been defined in line with these guidelines. Only
new and retreatment cases of pulmonary DS-TB and new cases of
MDR-TB and XDR-TB were considered in the analysis. All
outcome probabilities are shown in Table 2.
DS-TB. DS-TB patients are initially assessed and diagnosed at
a primary health care clinic and are followed up at subsequent
visits. Bacteriological monitoring tests are performed at diagnosis
and periodically during treatment, according to National TB
guidelines (Table S1). Xpert MTB-RIF is also performed on all TB
and DR-TB suspects at initial diagnosis only, in line with current
recommendations [5]. Treatment is initiated under the DOTS
program for the first two weeks at the clinic followed by
community-based DOTS treatment. The standard DS-TB treat-
ment regimen includes a 2-month intensive phase using 4 drugs
(isoniazid/rifampicin/ethambutol/pyrazinamide) followed by a 4-
month continuation phase (isoniazid/rifampicin). Retreatment
cases require 3 months of intensive phase treatment with
streptomycin included in the regimen, followed by a 5-month
continuation phase (isoniazid/rifampicin/ethambutol). Patients
who do not sputum convert (i.e. become smear negative) after
the initial intensive phase of treatment receive an extra month of
intensive phase treatment. We assume that DS-TB patients who
die or default from treatment only incur half the cost of a
treatment regimen [13]. Furthermore, as the vast majority of DS-
TB cases are treated in the community, we assume that no DS-TB
patients are hospitalized.
MDR-TB. Decentralized MDR-TB treatment in South Africa
was initiated in 2002, under the WHO DOTS-Plus program. The
national DR-TB guidelines recommend that the majority of cases
be treated as outpatients and only severely ill MDR-TB patients
should be admitted for hospitalization (10% of cases). Diagnostic
and monitoring tests are performed (Table S1) as recommended in
Table 1. Cont.
Cost Component Cost ($US) Source
1st line DST (Line Probe Assay) $26.74
2nd line DST for 4 drugs (MGIT 960 liquid culture) $37.83
Chest X-ray $31.91
Audiogram $25.60
Liver function (Potassium, Urea, Creatinine) $15.05
Kidney function (ALT, AST, Bilirubin) $10.86
Thyroid function $20.89
HIV Rapid screening test $5.26
Other HIV associated tests (CD4 count, viral load) $51.75






Surgery Groote Schuur Hospital
Pneumonectomy $5,549.36
Death i.e. Removal of body from premises $70.92 BCH financial department
DS-TB - Drug sensitive tuberculosis, MDR-TB – Multi-drug resistant tuberculosis, XDR-TB – Extensively Drug-resistant tuberculosis, ADR - Adverse Drug reaction, OT -
Occupational Therapist, PT - Physiotherapist, BCH – Brooklyn Chest Hospital, DOTS – Directly Observed Treatment Short Course, MGIT – Mycobacterial Growth In-tube,
DST – Drug susceptibility test, AST - aspartate aminotransferase, ALT - alanine aminotransferase, R - Rifampicin, H - Isoniazid, Z - Pyrazinamide, E - Ethambutol, S -
Streptomycin, Km – Kanamycin, Mxf - Moxifloxacin, Eto - Ethionamide, Trd – Terizidone, Cm - Capreomycin, PAS – para-amionsalicylic acid, Cfz – Clofazimine, Clm-
Clarithromycin, Aug - Augmentin, hdH - high dose Isoniazid.
doi:10.1371/journal.pone.0054587.t001
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the DR-TB management guidelines. We assume HIV infected
patients undergo six-monthly assessments of CD4 counts and
viral loads for the duration of TB treatment. A standardized
MDR-TB regimen consists of a 6-month intensive phase of
5 drugs (Ethionamide/Pyrazinimide/Kanamycin/Moxifloxacin/
Terizidone) followed by an 18-month continuation phase with 4
drugs (Ethionamide/Pyrazinimide/Moxifloxacin/Terizidone). In
addition to monthly hospital outpatient facility visits for scheduled
medical checkups, MDR-TB outpatients attend local TB clinics
daily to receive their drugs and monitoring for development of
ADRs. Inpatients remain hospitalized until they culture convert
(i.e. have two successive months of negative sputum cultures), then
continue treatment as outpatients, including daily attendance at
TB clinics for drugs and ADR monitoring during the continuation
phase of treatment. If patients do not culture convert after 12
months of treatment, they are considered treatment failures. We
assume these ‘non converters’ will be referred for XDR-TB
treatment and no longer incur MDR-TB associated costs.
XDR-TB. In South Africa, national DR-TB management
guidelines recommend hospitalization of all confirmed XDR-TB
patients. A standardized regimen for primary XDR-TB (25% of
XDR-TB cases [6,7]) consists of a 6–month intensive phase of 7
drugs (Ethionamide/Pyrazinimide/Capreomycin/Moxifloxacin/
Clofazimine/Terizidone/Para-aminosalycilic acid (PAS)) followed
by an 18-month continuation phase of 6 drugs (Ethionamide/
Pyrazinimide/Moxifloxacin/Clofazimine/Terizidone/PAS). An
acquired XDR-TB (75% of XDR-TB cases) treatment regimen
is the same except that ethionamide and terizidone are substituted
for augmentin, clarithromycin and high dose isoniazid. Clinic
visits, bacteriological, radiological and HIV monitoring tests are
performed with the same frequency as during MDR-TB
management. However, due to the increased toxicity of XDR-
TB drugs, such as capreomycin and PAS, we assume certain ADR
monitoring tests (kidney function tests, thyroid function test) are
performed more frequently (Table S1). In South Africa, provincial
review boards decide on whether or not to stop treatment in
patients who fail to culture convert after 12 months of XDR-TB
treatment. Based on clinical guidance, we assume that these
‘treatment failures’ are discharged from hospital after 12 months
but receive an extra 3 months of continuation phase treatment
before a review board decides to stop treatment completely.
Alternative XDR-TB decentralization programme. Due
to resource constraints on centralized treatment facilities, we
propose a decentralized programme where XDR-TB treatment is
Table 2. Per case probability estimates of different diagnosis- and treatment-related outcomes for drug sensitive, multi-drug
resistant and extensively-drug-resistant tuberculosis.
Outcome DS-TB MDR-TB XDR-TB
estimate source estimate source estimate source
Diagnostic outcomes and assumptions
HIV prevalence 0.50 [1] 0.60 [43] 0.60 [6–8]
Proportion of smear positives 0.6 [44] Not included*
Proportion of smear negatives 0.21 [44] Not included*
Proportion of retreatment cases 0.19 [44] Not included*
Treatment outcomes and assumptions
Proportion treated as hospital inpatients 0 Assumed{ 0.10 Assumed{ 1.00 0.5 [5] Assumed1
Proportion treated as hospital outpatients/PCC 1.00 Assumed{ 0.90 Assumed{ 0 0.5 [5] Assumed1
Duration of treatment (assuming treatment completion) 6 months [34] 2 years [5] 2 years [5]
Proportion who culture convert and complete treatment Not included" 0.50 [22,23,29] 0.20 [6,8]
Average time from diagnosis to culture conversion Not included" 4 months [23,29] 6 months [6,7]
Death during Treatment 0.05 [44] 0.20 [21,22,29] 0.40 [6–8]
Average time from diagnosis to death 3 months [13] 5 months [20,21] 7 months [6]
Treatment default 0.1 [44] 0.2 [20] Assumed same as MDR-TB
Time to treatment default 3 months [13] 5 months [13] Assumed same as MDR-TB
Treatment failure Not included" 0.10 [22,29] 0.40 [6]
Average time from diagnosis to treatment failure &
discharge from hospital
Not included" 12 months Assumed # 12 months [6]
Proportion developing ADRs 0.05 [25] 0.30 [26] 0.60 [6]
Proportion of patients developing ADRs that are
hospitalized
0.10 Assumed, [25] 0.30 [29] 0.60 [6]
Proportion undergoing surgery 0.00 Assumed 0.02 Assumed # 0.02 [6,24]
*These proportions were not included in the model as all MDR-TB and XDR-TB cases follow the same diagnosis and treatment protocols regardless of smear status in
accordance with national guidelines. Additionally, we only modelled new cases of MDR-TB and XDR-TB and did not include retreatment cases.
{Assumed that all DS-TB patients are treated at a primary care clinic and none are hospitalized.
{This estimate was provided by Brooklyn Chest Hospital.
1A figure of 50% is assumed for the decentralized XDR-TB model based on a proportion of patients from an XDR-TB cohort who weigh .50 kg,
"Not incorporated into our model as we assume all DS-TB patients complete a full course of treatment, whether they are cured or they fail treatment.
#Assumed to be the same as XDR-TB.
DS-TB - Drug sensitive tuberculosis, MDR-TB – Multi-drug resistant tuberculosis, XDR-TB – Extensively Drug-resistant tuberculosis, PCC - primary care clinic, ADR -
Adverse Drug reaction.
doi:10.1371/journal.pone.0054587.t002
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initiated in an outpatient facility and follow similar protocols to the
decentralized MDR-TB strategy. We estimate that approximately
50% of XDR-TB cases will be suitable for ambulatory care (based
on clinical experience and estimated by the proportion of XDR-
TB patients who weigh ,50 kg at diagnosis, which has shown to
be associated with worse treatment outcomes [6]). However, in the
absence of regulatory guidelines regarding the monitoring
frequency of XDR-TB outpatients and due to the poorer XDR-
TB outcomes, we assume these patients will be monitored more
closely than in MDR-TB. This includes hospital outpatient visits
twice a month during the intensive phase and monthly for the
continuation phase. We assume that monitoring tests will be
conducted with the same frequency as hospitalized patients and
XDR-TB drugs will continue to be dispensed at local TB clinics
for the entire course of treatment.
Sensitivity Analysis
A univariate sensitivity analysis was performed to measure
uncertainties in the component costs and outcome data used in the
analysis. Parameters that were varied include cost and length of
hospitalization, length of treatment, discount rate for capital items,
ADR prevalence, the incidence of surgery and the proportion of
MDR-TB and XDR-TB patients hospitalized. Additionally, the
inclusion of HIV ARV drug costs and HIV prevalence were varied
in the sensitivity analysis. HIV ARVs costs were determined for
the period of TB treatment and included 5 standard first-line drugs
(Efavirenz/Stavudine/Lamuvidine/Co-Trimoxizole/Pyridoxine)
given seven days a week.
Despite decentralized MDR-TB treatment being the current
policy in South Africa, many provinces still hospitalize the
majority of MDR-TB patients until culture conversion. We
therefore perform a sensitivity analysis to determine the per
patient and total national costs of MDR-TB assuming a higher
rate of hospitalization among MDR-TB patients (70% in South
Africa according to the WHO [5]).
Results
TB treatment costs and cost breakdown are shown in table 3.
The cost per case of smear-positive DS-TB was $191.66 whereas
the cost of a smear-negative and retreatment case was more
expensive, at $252.54 and $455.50 respectively, mainly due to the
increased number of diagnostic tests and the longer and more
expensive retreatment regimen. When the proportion of cases in
each category (smear positive, smear negative, retreatment), based
on 2010 TB case findings [1], was multiplied by the total costs of
each category, the overall cost of DS-TB was $256.61. The cost of
MDR-TB was much more expensive than DS-TB, at $5,930.02
for an MDR-TB outpatient and $14,348.94 for an MDR-TB
inpatient. We assumed that approximately 90% of MDR-TB cases
are treated as outpatients (according to national DR-TB guide-
lines) while the remainder are hospitalized due to severe illness.
Based on these proportions, the overall cost per case of MDR-TB
was $6,771.92. This cost was twenty-six times greater than DS-TB
with 49% of these costs being attributable to anti-MDR-TB drugs
(Figure 1). Conversely, all confirmed XDR-TB cases require
hospitalization. Management of an XDR-TB case costs
$26,392.01, four times greater than the cost of an MDR-TB case
and 103 times greater than that of a DS-TB case. While XDR-TB
drugs do make up a significant proportion of these costs (36%),
hospitalization contributes to 56% of the total XDR-TB costs
(Figure 1).
These costs were applied to a national level, where the total
number of notified pulmonary TB cases in 2010 in South Africa
[1,5] was used to obtain a generalized total cost spent on diagnosis
and treatment of confirmed TB (Figure 2). In terms of total cases,
only a small proportion were MDR-TB and XDR-TB (2% and
Table 3. Total costs and breakdown per patient for drug sensitive tuberculosis, multi-drug resistant tuberculosis and extensively
drug-resistant tuberculosis. Costs are expressed in $US.













Hospital inpatient stay $0.00 $0.00 $0.00 $0.00 $8,746.99 $0.00 $14,802.60
Hospital outpatient visit $0.00 $0.00 $0.00 $240.22 $130.16 $524.46 $105.40
PCC visit $32.85 $37.49 $76.98 $749.54 $498.08 $724.39 $240.82
Anti-TB drugs $40.24 $37.73 $188.48 $3,321.70 $3,321.70 $9,501.57 $9,501.57
Diagnostic/Monitoring Tests $112.30 $171.05 $183.77 $1,408.21 $1,413.28 $1,477.66 $1,409.97
ADRs $6.27 $6.27 $6.27 $99.37 $99.37 $192.29 $192.29
Surgery $0.00 $0.00 $0.00 $110.99 $110.99 $110.99 $110.99
Death $0.00 $0.00 $0.00 $0.00 $28.37 $0.00 $28.37
TOTAL $191.66 $252.54 $455.50 $5,930.02 $14,348.94 $12,531.36 $26,392.01
Prevalence in each group 0.60 0.20 0.20 0.90 0.10 0.00* 0.50 1.00* 0.50
Overall cost (group
prevalence x cost per
patient){
$256.61 $6771.92 Current strategy* $26,392.01
Decentralized strategy $19,461.68
*In the current model 100% of XDR-TB patients are hospitalized whereas in the proposed decentralized model 50% are treated as outpatients and the remaining 50%
are hospitalized.
{For example, the total costs of illness arising from DS TB per patient were calculated as (0.6*191.66)+(0.2*252.54)+(0.2*455.50) = $256.61.
DS-TB - Drug sensitive tuberculosis, MDR-TB – Multi-drug resistant tuberculosis, XDR-TB – Extensively Drug-resistant tuberculosis, PCC- primary care clinic, ADR- Adverse
Drug reaction.
doi:10.1371/journal.pone.0054587.t003
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0.2%, respectively) but these cases contributed to a significant
proportion of the total TB diagnosis and treatment costs (32% and
13%, respectively). Anti-TB drugs is a major contributor to the
total cost of TB diagnosis and treatment ($55 million) and DR-TB
drugs made up 58% of these costs (Figure 3).
We also proposed an alternative XDR-TB management
programme where healthier XDR-TB patients are managed
through hospital outpatient facilities and primary care clinics with
vigorous follow-up procedures. In this model, hospital costs were
eliminated which reduced the cost of diagnosing and treating an
XDR-TB case to $12,531.36, a cost saving of 53%. Furthermore,
we assume 50% of XDR-TB patients are suitable for ambulatory
care. If these patients are treated in the community while the
remainder are still treated as inpatients, then XDR-TB would cost
$19,461.68 per case and reduce the cost by $6930 compared to
current XDR-TB management practice.
We conducted a sensitivity analysis where model parameters
(costs and outcomes) were varied to assess any uncertainty in these
variables (Table 4). Inpatient day costs had the most significant
influence on XDR-TB costs followed by the proportion of patients
Figure 1. The cost breakdown of the total cost per patient for drug sensitive (DS-TB), multi-drug resistant (MDR-TB) and
extensively drug-resistant (XDR-TB) tuberculosis. *Other indicates surgery, ADRs and death related costs.
doi:10.1371/journal.pone.0054587.g001
Figure 2. The total number, national costs and cost breakdown of notified cases of drug sensitive (DS-TB), multi-drug resistant
(MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) reported in 2010. Costs are expressed in $US and refer to the cost of
diagnosis and treatment of confirmed cases. *Other indicates surgery, ADRs and death related costs.
doi:10.1371/journal.pone.0054587.g002
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treated as inpatients, which is not surprising as hospitalization
comprises a substantial proportion of per patient XDR-TB costs.
Similarly, the MDR-TB analysis was most sensitive to changes in
the proportion hospitalised and duration of treatment. Variation
in the proportion of non converters (treatment failures) also caused
noticeable changes in overall DR-TB costs, mainly due to the
increased length of hospitalization required in these individuals.
Overall costs of DS-TB, MDR-TB and XDR-TB changed
minimally when other parameters, such as inclusion of HIV
ARV drug costs, were varied.
Under the assumption of 70% hospitalization among MDR-TB
patients, the per patient cost of MDR-TB was $11,823, a
difference of $5,051 compared to MDR-TB costs in our primary
analysis ($6772 per case). Not surprisingly, inpatient costs
comprise the majority of these per patient costs (52%). Further-
more, in this scenario, MDR-TB costs constitute 49% of the total
national TB diagnosis and treatment costs (compared to 32% in
the primary analysis). Consequently, the national DR-TB diagno-
sis and treatment costs consume ,50% of the 2011 NTP budget.
Hospitalisation costs comprise the majority of the DR-TB national
costs (58%) under this assumption.
Discussion
We performed a cost analysis to determine the specific costs
associated with the diagnosis and treatment of MDR-TB and
XDR-TB in South Africa, including hospital inpatient and
outpatient, and primary care clinic costs, diagnostic and treatment
monitoring costs, drug costs, surgical costs, and costs associated
with HIV and ADR management. This is, to our knowledge, the
first study to accurately quantify the cost of treating XDR-TB and
the first to assess the costs of DR-TB management in South Africa
according to the current South African DR-TB guidelines. It will
facilitate planning and resource allocation, and will inform future
cost-effectiveness studies. Our main findings were (i) despite DR-
TB comprising only 2.2% of the total case burden it consumed
32% of the estimated 2011, ,US$218 million, total national TB
budget. (ii) XDR-TB consumed 28% of total DR-TB management
costs and 9% of the total national TB budget; (iii) overall, 45% and
25% of DR-TB costs were attributed to anti-TB drugs and
hospitalization, respectively (49% and 13% of MDR-TB costs;
36% and 56% of XDR costs, respectively); (iv) a decentralised
XDR-TB treatment model could reduce overall DR-TB costs by
,7% and the XDR-TB-specific costs by ,26%.
Despite DR-TB cases comprising a trivial proportion of the total
case burden they consumed a disproportionately large amount of
total TB costs. This was due to the high cost of managing DR-TB.
Indeed, despite the small number of total cases of XDR-TB (0.2%
of total notified cases in 2010), the cost was disproportionately
expensive ($26,392.01 per case and representing 9% of the
estimated total national TB costs). High drug prices [40] and the
need for extensive supervised patient care contribute to the high
cost of diagnosing and treating DR-TB. These costs (as a % of
total costs) are likely to increase substantially as the South African
Department of Health has recently recommended implementation
of the new Xpert MTB/RIF assay as the primary TB diagnostic
test in all persons with suspected TB [41]. This test, which also
detects rifampicin resistance, will likely increase the detection rate
and, consequently, the total costs of DR-TB [11]. Thus, effective
and sustainable financial and management strategies will be
required to deal with this expected rise in notified MDR-TB (and
XDR-TB) cases.
What are the major components driving the high DR-TB costs?
XDR-TB despite forming only 0.2% of the total case load
consumed ,26% of DR-TB diagnosis and treatment costs (and
,9% of total diagnosis and treatment costs). The major drivers
here were hospitalisation (56% of total XDR-TB costs) and drug
costs (36% of total XDR-TB costs). Drugs such as clarithromycin
and augmentin contributed to these costs (4% of total XDR-TB
drug costs) despite being of uncertain value in the effective
treatment of cases. Such costs could be diverted to other aspects of
the programme. By contrast, for MDR-TB laboratory testing and
anti-TB drugs comprised the majority (71%) of MDR-TB costs.
The MDR-TB per case costs in our study ($6,772) was different
compared to Russia (US$14,600) and Peru (US$2400) [17] mainly
reflecting differences in hospitalization and drug prices, but also
inclusion or exclusion of specific cost components.
A substantial proportion of DR-TB costs were attributed to
XDR-TB. Thus, targeting this component of DR-TB could
potentially reduce costs substantially. If, in contrast to the existing
model where all cases of XDR-TB are admitted to hospital, a
decentralized XDR-TB treatment strategy was adopted (where
patients receive their drugs and undergo routine clinical assess-
ments at their local TB clinics), costs savings of $6930 per case of
XDR-TB could potentially be made depending on the rate of
hospitalisation of these patients. These savings would primarily be
made through reduced hospitalization costs, which contribute to
over half of all XDR-TB costs. This is an attractive strategy
because DR-TB treatment facilities in South Africa are severely
overburdened [3] and there are often long waiting times for
limited bed space thus facilitating community transmission.
Indeed, in some areas like the Northern Cape out-patient
treatment of XDR-TB has already begun. Furthermore, lack of
proper infection control facilities in provinces like Kwa-Zulu Natal
results in nosocomial transmission, which may be responsible for
almost half of all XDR-TB cases in that province [42]. Given that
approximately 50% of patients meet these criteria XDR-TB-
related costs can be reduced by ,$6930 per case. Based on
notified XDR-TB cases in 2010, this represents a total savings of
US$5.1 million per annum (,2% of the National TB budget and
,7% of the estimated DR-TB budget). In addition to the potential
Figure 3. The total drugs costs of notified cases of drug
sensitive (DS-TB), multi-drug resistant (MDR-TB) and exten-
sively drug-resistant tuberculosis (XDR-TB) reported in 2010.
Costs are expressed in $US.
doi:10.1371/journal.pone.0054587.g003
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Baseline $256.61 $6,771.92 $26,392.01 $19,461.68
Discount rate
10% $261.33 $6,973.50 $28,514.62 $20,589.74
1% $255.55 $6,728.00 $25,934.11 $19,218.09
Treatment duration
30 months $256.61 $7,787.05 $27,111.95 $20,181.62
18 months $256.61 $5,813.29 $25,706.93 $18,776.61
Cost of Hospitalization/Outpatient visit
doubled $260.53 $7,965.52 $41,479.40 $27,357.31
halved $254.65 $6,175.11 $18,848.31 $15,513.87
HIV prevalence
90% $279.48 $6,825.74 $26,430.66 $19,500.34
30% $245.17 $6,718.09 $26,353.35 $19,423.03
HIV costs
Inclusion of ARVs (period of TB Treatment) $329.84 $7,012.12 $26,632.21 $19,701.88
ADR frequency
MDR
50% $256.61 $6,838.16 $26,392.01 $19,461.68
10% $256.61 $6,705.67 $26,392.01 $19,461.68
XDR
80% $256.61 $6,771.92 $26,456.10 $19,525.78
30% $256.61 $6,771.92 $26,295.86 $19,365.54
Surgery
10% $256.61 $7,215.86 $26,835.95 $19,905.63
1% $256.61 $6,716.42 $26,336.51 $19,406.19
Time to culture conversion (Length of
hospitalization)
MDR-TB
8 months $256.61 $7,095.49 $26,392.01 $19,461.68
2 months $256.61 $6,610.00 $26,392.01 $19,461.68
XDR-TB
12 months $256.61 $6,771.92 $28,327.12 $20,429.24
2 months $256.61 $6,771.92 $25,118.86 $18,825.11
% non converters
MDR-TB
50% $256.61 $5,828.11 $26,392.01 $19,461.68
30% $256.61 $6,300.01 $26,392.01 $19,461.68
XDR-TB
55% $256.61 $6,771.92 $27,362.82 $19,744.69
10% $256.61 $6,771.92 $24,450.37 $18,895.66
% hospitalized
MDR-TB
50% $256.61 $10,139.48 $26,392.01 $19,461.68
80% $256.61 $12,665.16 $26,392.01 $19,461.68
XDR-TB
90% $256.61 $6,771.92 $26,392.01 $25,005.94
10% $256.61 $6,771.92 $26,392.01 $13,917.42
DS-TB - Drug sensitive tuberculosis, MDR-TB – Multi-drug resistant tuberculosis, XDR-TB – Extensively Drug-resistant tuberculosis, ADR – Adverse Drug reaction, ARVs –
Anti-Retroviral drugs.
doi:10.1371/journal.pone.0054587.t004
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direct cost savings, a decentralized strategy would free up bed
space for patients with more extensive disease and encourage
treatment adherence among patients with limited access to these
centralized facilities. Decentralized MDR-TB management, cur-
rently performed in some provinces in South Africa, is a cost
effective option in other resource-poor settings as shown in our
analysis and elsewhere [17]. However, implementation of such a
strategy remains contentious as these patients need to be closely
monitored, (particularly for capreomycin-related electrolyte ab-
normalities) and educated in proper infection control practices.
Treatment default is also an issue which, in MDR-TB outpatients,
can be up to 20% [20].
There are a number of limitations to our analysis. Our study is a
simple cost analysis rather than a cost-effectiveness study, which
also evaluates effectiveness of a management strategy. However,
the purpose of our study was to report the costs of DR-TB in
South Africa rather than compare the cost-effectiveness of
different management strategies, which should be the focus of
future studies. The use of cost data from Brooklyn Chest Hospital
BCH is representative of the Western Cape but may not be reflect
the rest of South Africa as hospitalization and treatment facility
costs, as well as treatment regimens and some treatment policies
for DR-TB, can vary slightly across provinces. However, we used
standardized diagnosis and treatment protocols in our analysis,
according to South African national TB guidelines, and varied the
parameters that tend to be different across the provinces in the
sensitivity analysis. We used treatment outcomes from published
retrospective cohort studies due to lack of accurate surveillance
data and to generalize our results for South Africa. However, we
realize these results may not accurately reflect current disease
outcomes. While decentralized MDR-TB treatment is now the
current policy in South Africa, it is not fully implemented across all
provinces and our assumption of predominant outpatient care for
these patients may underestimate the cost of MDR-TB. However,
we conducted a sensitivity analysis using a higher estimate of
MDR-TB patients hospitalised (70%) and reported the per patient
and total national costs using this estimate. Indeed, an increased
incidence of inpatient care among MDR-TB patients does
increase the DR-TB costs. However, our analysis calculates DR-
TB costs based on adherence to current national DR-TB
management guidelines (which recommends outpatient care for
most MDR-TB cases) rather than the specific treatment practices
in other provinces. Strict implementation of decentralized MDR-
TB care is likely to become widespread across South Africa in the
near future. ADRs are difficult to cost as the frequency and types
of ADR varies widely among different cohort studies and one
patient may experience more than one ADR several times during
the course of treatment. Additionally, HIV infected individuals are
likely to have a higher frequency of ADRs due to additional drug
interaction with ARVs. As such, ADR costs may be underesti-
mated. Total national TB costs refers to costs associated with
diagnosis and treatment of confirmed TB cases and excludes
certain costs, such as those associated with diagnosis of non TB
cases. As such these costs may also be underestimated. Our
decentralized model for XDR-TB did not include detailed costs
associated with increased transmission or infection control. As
such, the cost-saving of this model is likely to be overestimated.
Future setting-specific detailed cost-feasibility studies are now
needed to determine the practicality of implementing this model.
Societal costs such as patient-related costs were not included as it is
difficult to accurately capture patients’ out of pocket expenses and
their socio-economic status during the time of illness. It is likely
that such costs will be substantial given the long hospitalization
periods, and extensive morbidity and mortality associated with
DR-TB. Assessment of these costs should be the focus of future
cost-analysis studies.
In conclusion, DR-TB in South Africa is extremely expensive
with a small number of DR-TB cases disproportionately consum-
ing a large chunk of the total NTP budget. Based on South African
National DR-TB guidelines, the current cost of XDR-TB
management is 103 times greater than DS-TB, the majority of
which is attributable to the cost of hospitalization. Implementation
of decentralized XDR-TB care is a viable option and can reduce
these costs but will require intensive follow up and appropriate
infection control measures to be put into place to minimise disease
transmission.
Supporting Information
Table S1 Frequency and duration of hospitalization,
outpatient/clinic visits, treatment and diagnostic/mon-
itoring tests during the period of treatment for drug
sensitive tuberculosis, multi-drug resistant tuberculosis
and extensively drug-resistant tuberculosis according to
the South African Drug Resistant TB guidelines. The
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